NPCE
NeuroPace, Inc.
NPCE has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over NPCE overall, supported by stronger fundamentals and stronger modeled upside.
NPCE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
NPCE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NPCE PE Valuation
NPCE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NPCE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NPCE's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NPCE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.18 |
| Q2 2026 | -$0.57 | +$0.25 |
| Q1 2026 | -$0.65 | +$0.17 |
| Q4 2025 | -$0.66 | +$0.27 |
| Q3 2025 | -$0.74 | +$0.25 |
| Q2 2025 | -$0.82 | +$0.26 |
| Q1 2025 | -$0.82 | +$0.36 |
| Q4 2024 | -$0.93 | +$0.34 |
NPCE is still losing money, but far less than before: $0.56 per share over the past year, against $1.91 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NPCE on earnings quality, reporting a profit while its opponent remains loss making.
NPCE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $23.1M | -16% |
| Q2 2026 | $22.8M | -3% |
| Q1 2026 | $22.1M | -2% |
| Q4 2025 | $26.6M | +24% |
| Q3 2025 | $27.4M | +30% |
| Q2 2025 | $23.5M | +22% |
| Q1 2025 | $22.5M | +24% |
| Q4 2024 | $21.5M | +19% |
NPCE's revenue fell from its 2025 peak and has held roughly level since: $23M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +0.5 points |
| Q2 2026 | -23% | +6.5 points |
| Q1 2026 | -25% | -2.4 points |
| Q4 2025 | -6.7% | +10 points |
| Q3 2025 | -9.5% | +11 points |
| Q2 2025 | -29% | +3.3 points |
| Q1 2025 | -23% | +19 points |
| Q4 2024 | -17% | +11 points |
NPCE's operating margin was −9% last quarter, up 0.5 points from the same quarter a year ago, near the top of its range since 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NPCE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NPCE on profitability, with a higher operating margin.
NPCE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -$805K |
| Q2 2026 | -$4M | -$1.8M |
| Q1 2026 | -$6M | +$1.5M |
| Q4 2025 | $409K | +$5.2M |
| Q3 2025 | -$2M | -$150K |
| Q2 2025 | -$2.3M | +$1.7M |
| Q1 2025 | -$7.5M | +$113K |
| Q4 2024 | -$4.8M | -$1.5M |
NPCE has burned cash in almost every quarter: −$12M over the past year, against −$17M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NPCE on cash generation, producing positive trailing cash flow while its opponent burns cash.
NPCE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +242K shares |
| 1 year | +3.7% | +1.2M shares |
| 3 years | +32% | +8.3M shares |
| 5 years | +96% | +16.8M shares |
NPCE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $49.5M |
| Q4 2020 | — |
NPCE hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NPCE Net Leverage
NPCE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NPCE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 7.3 | Oversold |
NPCE's weekly RSI is 39 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NPCE PE vs Healthcare Sector
NPCE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NPCE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.2% below |
| 20 week MA | $14.0 | 14% below |
| 50 week MA | $15.0 | 20% below |
| 100 week MA | $13.3 | 9.4% below |
| 200 week MA | $10.6 | 14% above |
NPCE has fallen below most of its moving averages, though it's still 14% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NPCE on trend strength, trading above more of its moving averages.
NPCE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.4 | $9.73 | -62% |
| 2022 | $9.73 | $1.36 | -86% |
| 2023 | $1.36 | $10.3 | +658% |
| 2024 | $10.3 | $10.7 | +3.5% |
| 2025 | $10.7 | $16.0 | +50% |
| 2026 YTD | $16.0 | $12.0 | -25% |
NPCE's yearly returns have swung widely, from +658% in 2023 to −86% in 2022. It's down 25% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NPCE on returns for 2026, with the stronger performance.